AccessibilityHelpAbout Us
Mesoblast logo

Mesoblast(OTC) MEOBF

Market Cap$2.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+70%
5 Year+29%
1 Year+23%
1 Month+12%
$1.90
+15.15%
+0.25Today
Mesoblast last closing stock price
MetricPriceDate
Last closeUSD 1.902026-08-28
Mesoblast stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.53%USD 1.892026-08-12
1 month+11.76%USD 1.702026-07-15
3 month+11.76%USD 1.702026-05-08
Year to date+0%USD 1.902025-12-22
1 year+23.38%USD 1.542025-08-22
3 year+542.11%USD 0.302023-08-29
5 year+29.25%USD 1.472021-08-25
Since inception+69.64%USD 1.122007-12-12

Mesoblast Financials at a Glance

Market Cap

$2.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$122.76M

Net Income (TTM)

-$57.50M

EPS (TTM)

-$0.04

P/E Ratio

-42.79

Dividend

$0.00

Beta (Volatility)

-0.14 (Low)

Price

$1.90

Volume

2

Open

$1.90

Previous Close

$1.90

Daily Range

$1.90 - $1.90

52-Week Range

$1.30 - $2.59

Estimated Earnings Date

Mar 4, 2027

MEOBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mesoblast

Mesoblast Limited is an Australian biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines. Established in 2004, the company operates globally, leveraging a proprietary regenerative medicine platform based on specialized mesenchymal lineage cells to address various medical conditions.

Products and Services
  • Remestemcel-L for steroid-refractory acute graft versus host disease
  • Rexlemestrocel-L targeting advanced chronic heart failure
  • MPC-06-ID for chronic low back pain from degenerative disc disease
Growth Outlook
  • Advanced pipeline includes several products in Phase III clinical trials
  • Strategic partnerships enhance market reach and product development
  • Focus on expanding applications in cardiovascular and inflammatory diseases
Financial Highlights
  • Recent quarterly revenue of $25.67 million, showing growth potential
  • Cash and cash equivalents of $129.58 million, providing operational stability
  • Trailing twelve months (TTM) net income margin of -1.44%, indicating ongoing investment in R&D
Mesoblast Limited is positioned in the biotechnology sector, focusing on innovative therapies that address significant unmet medical needs. The company's advanced pipeline and strategic partnerships are critical for its growth trajectory. Recent financial data indicates a solid cash position, which supports ongoing research and development efforts. The focus on regenerative medicine and cellular therapies places Mesoblast at the forefront of biopharmaceutical innovation, making it an intriguing option for potential investors interested in the healthcare sector.
AI Generated • Aug 27, 2026

Industry

Biotechnology

Sector

Health Care

Employees

108

CEO

Silviu Itescu, PhD

Website

www.mesoblast.com

Headquarters

Melbourne, VIC 3000, AU

MEOBF Financials

Key Financial Metrics (TTM)

Gross Margin

78.30%

Operating Margin

-96.11%

Net Income Margin

-46.79%

Return on Equity

-10.06%

Return on Capital

-7.52%

Return on Assets

-7.44%

Earnings Yield

-2.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.30B

Volume

2

Avg. Volume

30.20K

Financials (TTM)

Gross Profit

$96.22M

Operating Income

-$52.34M

EBITDA

-$45.01M

Operating Cash Flow

-$41.32M

Capital Expenditure

-$1.04M

Free Cash Flow

-$42.36M

Cash & ST Invst.

$102.91M

Total Debt

$127.33M

Mesoblast Performance Analysis

Mesoblast annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 7,501,000-26.5%
20242024-06-30USD 5,902,000-21.3%
20252025-06-30USD 17,198,000191.4%
20262026-06-30USD 120,250,000599.2%
Mesoblast sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30265.6%
Q22025-12-31N/A
Q32026-03-3134.2%
Q42026-06-307.3%
Mesoblast annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -0.11-21.3%
20242024-06-30USD -0.09-15.2%
20252025-06-30USD -0.08-5.1%
20262026-06-30USD -0.04-47.5%
Mesoblast sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-3027.2%
Q22025-12-31N/A
Q32026-03-3156.8%
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$36.97M

+426.5%

Gross Profit

$49.32M

+404.0%

Gross Margin

1.33%

N/A

Market Cap

$2.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$22.84M

N/A

Employees

108

N/A

Net Income

-$8.67M

+68.0%

EBITDA

-$9.97M

+49.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$102.91M

-36.1%

Total Debt

$127.33M

-0.6%

Accounts Receivable

$57.08M

+283.9%

Inventory

$28.11M

+26.4%

Long Term Debt

$113.71M

+59.4%

Short Term Debt

$13.63M

-76.0%

Return on Assets

-7.44%

N/A

Return on Invested Capital

-17.07%

N/A

Free Cash Flow

-$6.95M

+59.4%

Operating Cash Flow

-$6.74M

+59.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GENSFGenus plc
$31.07+0.00%
ONTTFOxford Nanopore Technologies plc
$2.05+0.00%
BRCTFBioArctic AB (publ)
$36.92+0.00%
PHMMFPharma Mar, S.A.
$94.60+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About MEOBF

What is the current price of Mesoblast?

Mesoblast is trading at $1.90 per share.

What is the 52-week range for Mesoblast?

Over the past 52 weeks, Mesoblast has traded between $1.30 and $2.59.

How much debt does Mesoblast have?

As of the most recent reporting period, Mesoblast reported total debt of $127.33M.

How much cash does Mesoblast have on hand?

Mesoblast reported $102.91M in cash and cash equivalents in its most recent financial results.

What is Mesoblast’s dividend yield?

Mesoblast does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services